Hydralazine hydrochloride and Gastroesophageal reflux disease - a phase IV clinical study of FDA data

Summary:

Gastroesophageal reflux disease is reported only by a few people who take Hydralazine Hydrochloride.

The phase IV clinical study analyzes which people take Hydralazine hydrochloride and have Gastroesophageal reflux disease. It is created by eHealthMe based on reports of 352 people who have side effects while taking Hydralazine hydrochloride from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 03, 2023

352 people reported to have side effects when taking Hydralazine hydrochloride.
Among them, 3 people (0.85%) have Gastroesophageal reflux disease.

What is Hydralazine hydrochloride?

Hydralazine hydrochloride has active ingredients of hydralazine hydrochloride. It is often used in high blood pressure. eHealthMe is studying from 754 Hydralazine hydrochloride users for its effectiveness, alternative drugs and more.

What is Gastroesophageal reflux disease?

Gastroesophageal reflux disease (a condition in which stomach contents leak backward from the stomach into the oesophagus) is found to be associated with 3,653 drugs and 3,201 conditions by eHealthMe.

Number of Hydralazine hydrochloride and Gastroesophageal reflux disease reports submitted per year:

Could Hydralazine hydrochloride cause Gastroesophageal reflux disease?

Gender of people who have Gastroesophageal reflux disease when taking Hydralazine hydrochloride *:

female: 66.67 %
male: 33.33 %

Age of people who have Gastroesophageal reflux disease when taking Hydralazine hydrochloride *:

Common drugs people take besides Hydralazine hydrochloride *:

Common side effects people have besides Gastroesophageal reflux disease *:

White Blood Cell Count Increased: 1 person, 33.33%
Red Cell Distribution Width Increased: 1 person, 33.33%
Agitation (state of anxiety or nervous excitement): 1 person, 33.33%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 1 person, 33.33%
Atrioventricular Block First Degree (heart block first degree): 1 person, 33.33%
Blood Bilirubin Increased: 1 person, 33.33%
Blood Creatine Phosphokinase Decreased: 1 person, 33.33%
Blood Glucose Increased: 1 person, 33.33%
Blood Sodium Decreased: 1 person, 33.33%
Blood Urea Increased: 1 person, 33.33%

Common conditions people have *:

Hyperlipidaemia (presence of excess lipids in the blood): 1 person, 33.33%

* Approximation only. Some reports may have incomplete information.

Do you take Hydralazine hydrochloride and have Gastroesophageal reflux disease?

Check whether Gastroesophageal reflux disease is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

COVID vaccines that are related to Gastroesophageal reflux disease:

Common drugs associated with Gastroesophageal reflux disease:

All the drugs that are associated with Gastroesophageal reflux disease:

Gastroesophageal reflux disease (3,653 drugs)

Common conditions associated with Gastroesophageal reflux disease:

High blood pressure: 8,283 reports
Osteoporosis: 6,304 reports
Pain: 4,963 reports

All the conditions that are associated with Gastroesophageal reflux disease:

Gastroesophageal reflux disease (3,201 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on hydralazine hydrochloride (the active ingredients of Hydralazine hydrochloride) and Hydralazine hydrochloride (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.